<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474773</url>
  </required_header>
  <id_info>
    <org_study_id>GA3190YM</org_study_id>
    <nct_id>NCT00474773</nct_id>
  </id_info>
  <brief_title>Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery</brief_title>
  <official_title>Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis Joint Replacement Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Louis Joint Replacement Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the benefits of continuing celecoxib through six weeks of total knee&#xD;
      arthroplasty recovery. This is a randomized, double blind study with a group of approximately&#xD;
      130 primary total knee patients. All patients will receive celecoxib throughout their&#xD;
      hospitalization as per current minimally invasive total knee arthroplasty protocol. At the&#xD;
      time of hospital discharge, participating patients will be randomly placed on either&#xD;
      celecoxib 200mg twice a day or a placebo twice a day.&#xD;
&#xD;
      This study will determine if the continued use of celecoxib for six weeks after total knee&#xD;
      arthroplasty hospitalization will further decrease narcotic consumption, improve knee range&#xD;
      of motion, improve ambulatory ability, and improve patient satisfaction over patients&#xD;
      receiving celecoxib only during the acute hospitalization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">107</enrollment>
  <condition>Pain Management</condition>
  <condition>Function</condition>
  <condition>Minimally Invasive Total Knee Arthroplasty</condition>
  <condition>Celecoxib</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        total knee canidates&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  having undergone a minimally invasive total knee by select surgeon&#xD;
&#xD;
          -  voluntarily enrolled&#xD;
&#xD;
          -  independent community ambulators&#xD;
&#xD;
          -  only patients being discharged directly home&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  celecoxib allergy or intolerence&#xD;
&#xD;
          -  Renal insufficiency (defined as serum creatine level &gt;1.5 mg/dL or BUN level &gt;22mg/dL&#xD;
&#xD;
          -  History of bleeding gastic or duodenal ulceration&#xD;
&#xD;
          -  New York Heart Association Class III or IV Congestive Heart Failure&#xD;
&#xD;
          -  Previous myocardial infarction or cerebralvascular event&#xD;
&#xD;
          -  Severe inflammatory bowel disease&#xD;
&#xD;
          -  Known coagulation abnormality or hepatic disease&#xD;
&#xD;
          -  Chronic coumadin administration&#xD;
&#xD;
          -  Refusal by primary or cardiac physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>William C Schroer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis Joint Replacement Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DePaul Health Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>May 15, 2007</study_first_submitted>
  <study_first_submitted_qc>May 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

